Novartis AG (NVS) |
| 153.76 1.03 (0.67%) 07-17 16:00 |
| Open: | 153.885 |
| High: | 155.3 |
| Low: | 153.14 |
| Volume: | 2,424,703 |
| Market Cap: | 293,388(M) |
| PE Ratio: | 17.69 |
| Exchange: | New York Stock Exchange |
| Industry: | Drug Manufacturers - General |
| Sector: | Healthcare |
| Technical analysis | ||||
 |
||||
| sell | buy | |||
| Resistance 2: | 187.55 |
| Resistance 1: | 160.57 |
| Pivot price: | 154.74 |
| Support 1: | 151.94 |
| Support 2: | 146.60 |
| 52w High: | 170.46 |
| 52w Low: | 112.34 |
Novartis AG is a holding company, which engages in the business of developing, manufacturing, and marketing healthcare products. Its product portfolio is heavily focused on innovative prescription medicines, especially oncology, immunology, neuroscience, and cardiovascular diseases, supplemented by established older brands and a wide range of specialized therapies. The company was founded on February 29, 1996 and is headquartered in Basel, Switzerland.
Financials
| EPS | 6.950 |
| Book Value | 20.180 |
| PEG Ratio | 4.18 |
| Gross Profit | 22.382 |
| Profit Margin (%) | 23.92 |
| Operating Margin (%) | 30.48 |
| Return on Assets (ttm) | 10.5 |
| Return on Equity (ttm) | 34.9 |
Company news
Fri, 17 Jul 2026
This Novartis Drug Could Help Delay Dialysis—FDA Grants Full Approval - Benzinga
Fri, 17 Jul 2026
Novartis wins full FDA approval for kidney disease drug Fabhalta in IgA nephropathy - Seeking Alpha
Thu, 16 Jul 2026
Novartis AG (TSX:NVS) Stock Price, Trades & News - GuruFocus
Thu, 16 Jul 2026
Gear Up for Novartis (NVS) Q2 Earnings: Wall Street Estimates for Key Metrics - Yahoo Finance
Wed, 15 Jul 2026
Earnings Preview: Novartis AG to Report Financial Results on July 21 - Moomoo
Thu, 09 Jul 2026
NVS News | NOVARTIS AG-SPONSORED ADR (NYSE:NVS) - ChartMill
 StockChart iOS |
 StoxlineLite iOS |
StoxlineLite iOS |
 OptionCalc iOS |
|
StockChart Android |
StoxlineLite Android |
StoxlinePro Android |
OptionCalc Android |
